Cargando…
Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries
BACKGROUND: As alternatives to warfarin, 2 novel oral anticoagulants (NOACs), dabigatran and rivaroxaban, were approved in 2010 and 2011 to prevent stroke and other thromboembolic events in patients with atrial fibrillation. It is unclear how patient characteristics are associated with the initiatio...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051348/ https://www.ncbi.nlm.nih.gov/pubmed/27003558 http://dx.doi.org/10.18553/jmcp.2016.22.3.281 |